-
1
Emerging insights into intravital imaging, unraveling its role in cancer immunotherapy
Published 2025-02-01“…Abstract Cancer immunotherapy has attracted great attention as a potential therapeutic approach for advanced malignancies due to its promising survival benefits. …”
Get full text
Article -
2
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
Published 2025-02-01Get full text
Article -
3
Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
Published 2024-05-01Get full text
Article -
4
-
5
Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
Published 2022-03-01“…The generation of TCR-like antibody and its CAR-T cells provides the state-of-the-art platform and proof-of-concept validation to broaden the scope of target antigen recognition and sheds light on the development of novel therapeutics for cancer immunotherapy.…”
Get full text
Article -
6
Harnessing amino acid pathways to influence myeloid cell function in tumor immunity
Published 2025-02-01Subjects: Get full text
Article -
7
Profile of STING agonist and inhibitor research: a bibliometric analysis
Published 2025-02-01Subjects: Get full text
Article -
8
CD32B1, a versatile non-signaling antibody-binding scaffold for enhanced T cell adhesion to tumor stromal cognate antigens
Published 2025-02-01Subjects: “…cancer immunotherapy…”
Get full text
Article -
9
-
10
A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types
Published 2025-02-01Get full text
Article -
11
-
12
Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
Published 2022-10-01“…Therefore, a better understanding of the molecular mechanism responsible for T cell senescence in the TME and development of novel strategies to prevent effector T cell senescence are urgently needed for cancer immunotherapy.Methods Senescent T cell populations in the TMEs in mouse lung cancer, breast cancer, and melanoma tumor models were evaluated. …”
Get full text
Article -
13
Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care
Published 2025-01-01Get full text
Article -
14
Exosomes, their sources, and possible uses in cancer therapy in the era of personalized medicine
Published 2024-12-01Get full text
Article -
15
Recent advances of nanovaccines on cancer theranostics
Published 2025-02-01“…This paper reviewed the research progress of some nanovaccines in cancer immunotherapy, including polymer nanoparticle vaccine, liposome nanoparticle vaccine, cell-based nanoparticle vaccine, inorganic nanoparticle vaccine, adjuvant and auxiliary work. …”
Get full text
Article -
16
Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma
Published 2025-02-01“…Recently, cell-based immunotherapy using natural killer (NK) cells has attracted considerable attention in cancer immunotherapy. NK cells generated from induced pluripotent stem cells (iPSCs) are a new option for use as an NK cell resource. …”
Get full text
Article -
17
Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites
Published 2025-02-01“…Here we investigate the impact of plant-derived nanoparticles (PNP) on gut microbiota and metabolites in context of cancer immunotherapy with the humanized gnotobiotic mouse model. …”
Get full text
Article -
18
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
Published 2022-03-01“…Therefore, LTX-315, or the development of ATP11B-targeting drugs, might improve the efficacy of cancer immunotherapy.…”
Get full text
Article -
19
Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer
Published 2025-02-01“…Current pancreatic cancer immunotherapy focused on alphabeta (αβ) T cells, either through CD3-engaged bispecific antibodies or CAR-T. …”
Get full text
Article -
20
Immunogenic dying cells elicit potent anti-tumor T cell immunity against lung metastasis and tumorigenesis
Published 2025-01-01“…Conclusion Immunization with the ICD dying tumor cells evokes potent tumor-specific T cell immunity, which provides a novel approach for cancer immunotherapy.…”
Get full text
Article